

Research in the biology, treatment, detection, and prevention of disease;

I. Experience in publishing biomedical research;

J. Demonstrated proficiency in serving a large membership base.

2. Reputation:

The successful Collaborator must be recognized in the biomedical research and clinical practice communities for:

A. The quality of its information products, particularly its biomedical journals;

B. Its commitment to the advancement of science and medical practice;

C. Indications of high levels of satisfaction by health professionals with the information products and services;

D. The range of products and services;

E. The impact of its journal(s) as measured by the Institute for Scientific Information (ISI).

3. Physical Resources:

A. An established headquarters with offices, space and equipment;

B. Personal access to the organization during business hours;

C. Access to the organization during business hours by telephone, mail, e-mail, the Internet and other evolving technologies;

D. Sufficient financial resources to support, at a minimum, the current activities of the NCI to meet the needs of the National Cancer Program.

Dated: October 26, 1995.

Thomas Mays,

Director, Office of Technology Development, National Cancer Institute, National Institutes of Health.

[FR Doc. 95-27322 Filed 11-2-95; 8:45 am]

BILLING CODE 4140-01-P

### Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health.

ACTION: Notice.

The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for U.S. companies and may also be available for licensing.

ADDRESSES: Licensing information and a copy of the U.S. patent application and/or the issued patent referenced below may be obtained by contacting the indicated Licensing Specialist at the Office of Technology Transfer, National Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville, Maryland 20852-3804 (telephone 301/496-7735; fax 301/402-0220). A signed Confidential Disclosure Agreement will be required to receive a copy of the patent application.

Monoclonal Antibodies for Binding HTLV-III (HIV-1) Proteins, and Cell Lines for Their Production

Sarnagadharan, M., Veronese, F., Gallo, R. (NCI)

Serial No. 06/816,573

Patent Issued 27 June 89

U.S. Patent No. 4,843,011

Licensing Contact: Steven Ferguson, 301/496-7735 ext 266

Monoclonal antibodies and hybridoma cell lines for their production are disclosed for three specific proteins that characterize HIV-1, the virus that has been identified with AIDS. This invention relates to all monoclonal antibodies that demonstrate immune reactivity with specific antigens that identify the HIV-1 virus: p41, a transmembrane envelope glycoprotein; p24, a major core protein; and p17. These antibodies provide a means for directly detecting the virus in the sera, blood or blood products of AIDS patients or HIV-1 carriers. Such methods are an important advance over the indirect antibody detection methods presently used. Methods based on antibody detection give false negatives if no antibodies have yet been produced. These antibodies are believed to provide a positive indication of the presence of the virus at any stage of the disease in a patient or in a healthy carrier of virus.

Sterile-Lyophilization Tube

Kidd, G.L. (NEI)

Filed 22 Sep 95

DHHS Reference No.: E-015-95/0

Licensing Contact: David Sadowski, 301/496-7735 ext. 288

*Problem Addressed by This Invention:* Many compounds, such as drugs, growth factors, etc., must be kept sterile and must be aliquotted for storage. Usually, these aliquots are best stored lyophilized. Yet, researchers have never had a way to keep aliquots sterile through the lyophilization process. Consequently, each aliquot has had to be filter-sterilized when reconstituted for use. This process has the disadvantages of consuming excessive filters, syringes, sterile, receptacles, and time and results in serious loss of precious sample due to absorption by the filters (especially with small aliquots less than 1 ml). Alternatively, researchers have had to forego lyophilization and store their solutions in the less-stable frozen form.

*Solution Offered by This Invention:* Sterile-lyophilization tubes having a 0.22 micron filter built into the cap. This unique feature allows a sterile solution to remain sterile throughout lyophilization, even after the vacuum is released and air reenters the tube. Thus, a starting solution is simply filter-sterilized while in a relatively large volume, using a single filter and therefore suffering minimal loss and consuming little time. It is then aliquotted into sterile-lyophilization tubes and lyophilized. The tubes can then be transferred directly to the freezer, if desired. The compound is reconstituted when needed, and may then be used immediately without further filtration.

*Potential Applications of This Invention:* All researchers worldwide who utilize sterile, labile compounds will have an interest in this product, including governmental, university, institutional, and drug company laboratories. Most notably in need are investigators involved in drug-testing, which is normally done either in cell cultures, laboratory animals, or humans, and which requires sterility of many aliquots of many drugs. Additionally, this product will have a large market relating to basic research utilizing microbial, plant, or animal cell or organ cultures, to which sterile compounds such as growth factors are commonly added. Research in drugs, growth factors, etc., is expanding ever more rapidly, and generally requires a cell culture system in which to study such compounds. Most of these compounds are quite expensive. Loss of potency during storage and loss of material during filtration are widespread problems which may be overcome with this invention. Therefore, there exists a tremendous need, and immense market for, this sterile-lyophilization vessel.

*Stage of Development:* Development is complete and invention has been successfully tested. Prototypes are available.

Dated: October 26, 1995.

Barbara M. McGarey,

Deputy Director, Office of Technology Transfer.

[FR Doc. 95-27321 Filed 11-2-95; 8:45 am]

BILLING CODE 4140-01-P

### Notice of the Meeting of the National Eye Institute Board of Scientific Counselors

Pursuant to Pub. L. 92-463, notice is hereby given of the meeting of the Board of Scientific Counselors, National Eye Institute (NEI), December 4 and 5, 1995 in the NEI Conference Room, Building

31, Room 6A35, National Institutes of Health, Bethesda, Maryland.

This meeting will be open to the public on December 4 from 9 a.m. until approximately 4 p.m. for general remarks by the Director, Intramural Research Program, NEI, on matters concerning the intramural program of the NEI. Attendance by the public will be limited to space available.

In accordance with provisions set forth in sec. 552b(c)(6), Title 5, U.S.C. and sec. 10(d) of Pub. L. 92-463, the meeting will be closed to the public on December 4 from approximately 4 p.m. until recess and on December 5 from 8:30 a.m. until adjournment for the review, discussion, and evaluation of individual projects conducted by the Laboratory of Mechanisms of Ocular Diseases and the Laboratory of Ocular Therapeutics. These evaluations and discussions could reveal personal information concerning individuals associated with the projects, including consideration of personnel qualifications and performance, and the competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Consequently, this meeting is concerned with matters exempt from mandatory disclosure.

Ms. Marie Watkins, Committee Management Officer, NEI, EPS/350, Bethesda, Maryland 20892, (301) 496-5301, will provide a summary of the meeting, roster of committee members, and substantive program information upon request. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact Ms. Watkins in advance of the meeting.

(Catalog of Federal Domestic Assistance Program No. 93.867, Vision Research; National Institutes of Health)

Dated: October 30, 1995.

Susan K. Feldman,

*Committee Management Officer, NIH.*

[FR Doc. 95-27250 Filed 11-2-95; 8:45 am]

BILLING CODE 4140-01-M

### **National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting**

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Institute of Allergy and Infectious Diseases Special Emphasis Panel (SEP) meeting:

*Name of SEP:* AIDS-Related Training Grants, Conference Grants, Clinical Investigator and Independent Scientist Applications.

*Date:* November 13, 1995.

*Time:* 8 a.m.

*Place:* NIH, Natcher Bldg. 45, Conference Room A, 9000 Rockville Pike, Bethesda, MD 20892.

*Contact Person:* Dr. Peter Jackson, Scientific Review Adm., 6003 Executive Boulevard, Solar Bldg., Room 4C10, Bethesda, MD 20892-7610, (301) 496-8426.

*Purpose/Agenda:* To review grant applications.

The meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than 15 days prior to the meeting due to the urgent need to meet timing limitations imposed by the grant review cycle.

(Catalog of Federal Domestic Assistance Programs Nos. 93.855, Immunology, Allergic and Immunologic Diseases Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health.)

Dated: October 30, 1995.

Susan K. Feldman,

*Committee Management Officer, NIH.*

[FR Doc. 95-27251 Filed 11-2-95; 8:45 am]

BILLING CODE 4140-01-M

### **National Institutes of Arthritis and Musculoskeletal and Skin Diseases; Notice of Closed Meeting**

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting:

*Name of Committee:* Arthritis and Musculoskeletal and Skin Diseases Special Grants Review Committee.

*Date:* November 20, 1995, November 21, 1995.

*Time:* 6:30 p.m.

*Place:* Bethesda Marriott, 5151 Pooks Hill Road, Bethesda, Maryland.

*Contact Person:* Theresa Lo, Ph.D., Scientific Review Administrator, Natcher Building, 45 Center Drive, Room 5AS-25U, Bethesda, Maryland 20892-6500, (301) 594-4952.

*Purpose/Agenda:* To review and evaluate research grant applications.

The meeting will be closed in accordance with the provisions set forth in sec. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the

applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Nos. [93.846, project grants in arthritis, musculoskeletal and skin diseases research], National Institutes of Health, HHS)

Date: October 30, 1995.

Susan K. Feldman,

*Committee Management Officer, NIH.*

FR Doc. 95-27253 Filed 11-2-95; 8:45 am]

BILLING CODE 4140-01-M

### **National Institute of Child Health and Human Development; Notice of Meeting of the Board of Scientific Counselors, NICHD**

Pursuant to Pub. L. 92-463, notice is hereby given to the meeting of the Board of Scientific Counselors, National Institute of Child Health and Human Development, December 1, 1995, in Building 31, Room 2A52.

This meeting will be open to the public from 8:00 a.m. to 12 noon on December 1 for the review of the Intramural Research Program and scientific presentations. Attendance by the public will be limited to space available.

In accordance with the provisions set forth in sec. 552b(c)(6), Title 5, U.S.C. and sec. 10(d) of Pub. L. 92-463, the meeting will be closed to the public on December 1 from 1 p.m. to adjournment for the review, discussion, and evaluation of individual programs and projects conducted by the National Institutes of Health, including consideration of personnel qualifications and performance, the competence of individual investigators, and similar items, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Ms. Catherine O'Connor, Senior Biomedical Research Program Assistant, NICHD, Building 31, Room 2A50, National Institutes of Health, Bethesda, Maryland, 20892-2425, Area Code 301, 496-2133, will provide a summary of the meeting and a roster of Board members, and substantive program information upon request. Individuals who plan to attend the open session and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact Ms. O'Connor in advance of the meeting.

Dated: October 30, 1995.

Susan K. Feldman,

*Committee Management Officer, NIH.*

[FR Doc. 95-27317 Filed 11-2-95; 8:45 am]

BILLING CODE 4140-01-M